Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-01
2005-02-01
Nickol, Gary (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S094100, C424S094500, C435S233000, C530S399000
Reexamination Certificate
active
06849599
ABSTRACT:
The invention provides antineoplastic composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase type I enzyme activity.
REFERENCES:
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5670507 (1997-09-01), Rice et al.
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5840692 (1998-11-01), Deutch et al.
patent: 5843994 (1998-12-01), Samid
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 5994309 (1999-11-01), Mazar et al.
patent: 5994341 (1999-11-01), Hunter et al.
patent: 6100273 (2000-08-01), Besterman et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: WO 9110424 (1991-07-01), None
patent: WO 9214470 (1992-09-01), None
patent: WO 9309782 (1993-05-01), None
patent: WO 9601127 (1996-01-01), None
patent: WO 9843618 (1998-10-01), None
patent: WO 9910523 (1999-03-01), None
patent: WO 9910524 (1999-03-01), None
patent: WO 9910525 (1999-03-01), None
patent: WO 9954445 (1999-10-01), None
O'Leary et al. (Clinical Cancer Res. Jan. 1999; 5:181-187).*
Sheibani et al. (Biochem Biophys Res commun Jan. 7, 2000; 267(1):257-61,).*
Streit et al. (Proc Natl Acad Sci USA Dec. 21, 1999; 96(26):14888-93).*
Biosciences Information Service. (2000). Database Accession No. PREV200000275647 (XP002180182).
International Search Report. PCT/ US 01/ 07472. Issued on Dec. 13, 2001.
Clements et al., “Antiangiogenic potential of camptothecin and topotecan,” Cancer Chemotherapy and Pharmacology, V44, N1, p. 39-48.
Clements et al., “Inhibition of Angiogenesis and Proliferation of Normal Endothelial Cells by Camptothecin,” 1998, FASEB J., N5, 2, S(Mar. 20), p. 5499.
Clements et al., “Camptothecin exhibits selective cytotocicity towards human breast carcinoma as compared to normal bovine endothelial cells in vitro,” 1996, Anticancer Drugs 7:851.
Guo et al., “Thrombospondin 1 and Type I Repeat Peptides of Thrombospondin 1 Specifically Induce Apoptosis of Endothelial Cells,” Cancer Res. 57/9 (1735-1742).
Hsiang et al., “DNA Topoisomerase I-mediated DNA Cleavage and Cytotoxicity of Camptothecin Analogues,” 1989, Cancer Research, 49:4385-4389.
Jaxel et al., “Structure-Activity Study of the Actions of Camptothecin Derivatives on Mammalian Topoisomersae I: Evidence for a Specific Receptor Site and a Relation to Antitumor Activity,” Cancer Research. 49:1465-1469.
Kakeji et al., “Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents,” Investigational New Drugs, 7(1):39-48.
Kantarjian et al., “New Developments in the Treatment of Acute Myeloid Leukemia: Focus on Topotecan,” Seminars in Hemotology, 36/4 Suppl. 8 (16-5).
O'Leary et al., “Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20(S)-camptothecin, Topotecan, and CPT-11 Studies in the Mouse,” 1999, Clinical Cancer Research, 5:181-7.
Polverini et al., “Assay and Purification of Naturally Occuring Inhibitor of Angiogenesis,” 1991, Methods. Enzymol. 198:440-450.
Calabresi Paul
Darnowski James
Beattie Ingrid A.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Nickol Gary
Rhode Island Hospital
Yaen Christopher
LandOfFree
Combination drug therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination drug therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination drug therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487301